Intensity Therapeutics (INTS) has a profit margin of 46292.31%, above the sector sector average of 13.23%.
Get informed when a big investor buys or sells
+ FollowAs of Sep 2026
Trailing 12 months ending Sep 2026
Intensity Therapeutics (INTS) currently reports a profit margin of 46292.31% as of September 2026. That is above the sector sector average of 13.23%. Use the charts on this page to explore Intensity Therapeutics's profit margin history and peer comparisons.
Intensity Therapeutics's profit margin of 46292.31% is higher than the its sector sector average of 13.23%. That is roughly 349906.2% above the sector mean. A reading higher peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.
There is no universal 'good' profit margin, but Intensity Therapeutics's current 46292.31% should be judged against industry norms (sector average: 13.23%) and against INTS's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.
Start with the current profit margin of 46292.31%, then check the historical chart for trend and the peer comparison chart for relative positioning. The sector average is 13.23%. From there, open related valuation or income-statement pages for Intensity Therapeutics, and consider following INTS for alerts when major investors trade the stock.